Business Context and Reporting Period
This summary covers the Form 10-Q for iGambit Inc. (Note: The input metadata referenced "Nutex Health Inc.", but the filing text explicitly identifies the registrant as iGambit Inc.) for the quarterly and six-month periods ended June 30, 2019. iGambit is a holding company focused on medical technology markets, primarily through its wholly-owned subsidiary, HealthDatix Inc., which provides Software-as-a-Service (SaaS) solutions for healthcare data management, remote patient monitoring, and chronic care management.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 |
|---|---|---|
| Revenue | $11,625 | $7,918 |
| Net Loss | $(1,129,762) | $(1,336,280) |
| Operating Loss | $(741,821) | $(900,978) |
| Cash and Cash Equivalents | $75,456 | $50,917 |
| Total Assets | $2,338,814 | $2,618,466 |
| Total Liabilities | $1,325,133 | $1,385,447 |
| Stockholders' Equity | $1,013,681 | $1,233,019 |
| Working Capital | $(1,212,323) | $(1,343,134) |
| Notes Payable | $445,593 | $52,500 |
| Convertible Notes Payable | $72,254 | $377,611 |
Note: Gross profit was negative for both periods due to costs exceeding the minimal revenue generated by the subsidiary.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by approximately 47% year-over-year (from $7,918 to $11,625), driven by HealthDatix operations.
- Reduced Net Loss: The net loss decreased by roughly 15% compared to the prior six-month period, primarily due to a gain on the change in fair value of derivative liabilities ($98,944) and reduced operating expenses.
- Debt Restructuring: Significant activity occurred in debt management. The company converted approximately $326,189 of principal and $19,868 of accrued interest into 182.7 million shares of common stock. Additionally, a new secured promissory note of $393,093 was obtained from Clinigence Holdings, Inc., used largely to pay off existing convertible notes.
- Derivative Liability: The derivative liability balance dropped to zero from $288,242 at the end of 2018, resulting in a non-cash gain of $98,944.
- Operating Expenses: General and administrative expenses decreased by approximately 29% year-over-year, attributed to reductions in payroll, consulting fees, and bank service fees.
Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $13.6 million and a working capital deficit of $1.2 million. Continuation depends on obtaining equity financing and generating revenue.
- Merger Agreement: On August 9, 2019 (subsequent to the reporting period), iGambit entered into a definitive merger agreement with Clinigence Holdings, Inc. Upon closing, former Clinigence equityholders will own 85% of the combined entity, while former iGambit shareholders will own 15%.
- Financing Needs: The company anticipates needing additional capital to fund operations and expansion. It has no lines of credit and relies on private placements of equity and debt, which may result in significant dilution.
- Unusual Items: The income statement includes significant non-operating items, including a $262,566 loss on extinguishment of debt and a $98,944 gain on the change in fair value of derivative liabilities.
Investor Verification Checklist
- Merger Terms: Verify the final terms and closing status of the merger with Clinigence Holdings, Inc., specifically the 85/15 equity split and potential dilution to existing shareholders.
- Liquidity Runway: Assess the sufficiency of the $75,456 cash balance against the working capital deficit and upcoming operational costs.
- Debt Obligations: Review the terms of the new $393,093 note payable to Clinigence, including the 6% interest rate and maturity conditions tied to the merger.
- Revenue Concentration: Note that one customer accounted for 96% of accounts receivable and two customers accounted for 38% of sales, indicating high concentration risk.
- Stock Dilution: Confirm the impact of the 182.7 million shares issued for debt conversion and the potential issuance of new shares for the merger.